- Reaction score
- 222
Wasn’t finasteride launched 20 years ago?
Italian Hair Loss Lotion To Hit The Market In 2016
- Thread starter paleocapa89
- Start date
br1
Senior Member
- Reaction score
- 2,163
Propecia, maybe. But proscar was available way earlier.
- Reaction score
- 222
damn he is a nice guy. bring him back mod.
Team pessimism takes its first of many Ls this April.
- Reaction score
- 1,709
Perhaps because he spammed @beps63 literally hundreds of times within one post.
That being said, I do hope it wasn't a permaban. That seems excessive for such a harmless prank.
R.I.P.
- Reaction score
- 4,609
Big reveal of our shiny baldness?
That was a reveal that happened a while ago unfortunately
Guys, exactly 1,5 years ago, I was hyped, not because I thought this is going to be a miracle but because I thought release was soon.
I was pretty sure (as I am now) that the Brotion is going to help hairloss sufferers. In which amount has to be proofed.
Then there was the fidia update with the sentence „BY 2018“ so it was pretty sure that there was a long time without anything.
Now there are only 12 days left until we will finally see what we can expect. And I must admit, I am pretty excited.
Over 2,5 years of waiting and in less then 2 weeks I can finally stop checking this thread. Don’t know what to do with all the new freetime... maybe Iam going to solve the world hunger problem.
I was pretty sure (as I am now) that the Brotion is going to help hairloss sufferers. In which amount has to be proofed.
Then there was the fidia update with the sentence „BY 2018“ so it was pretty sure that there was a long time without anything.
Now there are only 12 days left until we will finally see what we can expect. And I must admit, I am pretty excited.
Over 2,5 years of waiting and in less then 2 weeks I can finally stop checking this thread. Don’t know what to do with all the new freetime... maybe Iam going to solve the world hunger problem.
Hi guys, I'm a member of Bellicapelli, the most important italian forum on hairloss. I don't know if you know, so I registered on this purpose, that has been discovered yesterday that the lotion will be in commerce in October 2018 (according to the opinion of one of the responsible of the project in Fidia). I can't say to you nothing else more, 'cause this information is strictly reserved. I hope that Brotzu will confirm this in the conference of 14 April.
- Reaction score
- 64
I think we should all urge a little bit of caution re this April 14th conference. We should find out at least to some degree how effective this is but we have no reason to believe we’ll learn the release date, which I feel a lot of you are anticipating. There’s so much to be optimistic about but you just know that the slightest let down will send this forum into meltdown so let’s not expect too much from this conference.
- Reaction score
- 4,504
I also heard October 2018 from a doctor who has an "inside source" and kindly showed me the convo they had.
Let us hope the date is right and the product works well as it now seems...
- Reaction score
- 775
I feel like 2018 will be my best year yet, not just because of this but a bunch of other things too. Fingers crossed. Really do believe it'll be out this year =)
- Reaction score
- 1,253
It better work, I’ll be like Norwood 4
This isn't going to be Elon Musk unveiling a new model or Tim Cook a new Iphone. It's a scientific presention, we're getting clinical data and nothing more on the 14th.
- Reaction score
- 1,126
All I want from this conference is to give us solid insight on how effective the product will be, so one can plan accordingly.
On April the 14th I will either party with strippers and cocaine or begin arranging a mass suicide event for gourmetstylewellness.com members.
- Reaction score
- 3,659
- Reaction score
- 37
Patent update
https://patents.google.com/patent/EP3145490A1/en
"Clinical trials that were carried out further demonstrated a surprisingly higher efficacy of the products described herein in comparison with what is known, so as to make their use possible at concentrations markedly lower than those of already known products."
"
Lotions, eventually, can also be dispensed from "spray no-gas", then propellant free, bottles.
Additionally, it is possible to administer liposomes by oral route after having them properly delivered in capsules of gelatine or other substances suitable for the purpose and known to the expert in the field.
Regardless of the selected pharmaceutical form, it is clear that all excipients and all tactics known to the technical formulator in order to ensure stability, storability, absence of contamination, etc. of the preparations will be employed."
"The present invention relates to pharmaceutical compositions for the treatment of alopecia, baldness, hair loss, also in postmenopausal women, and in general to promote hair regrowth"
"Experimental study
Patients of female and male gender characterized by massive hair reduction due to various causes, and also a small number of patients of female gender of postmenopausal age, reporting hair thinning, hair reduction and loss of hair strength were selected."
"Results
On day 7 : both group 1 and group 2 experience a reduction of hair loss, defined "substantial" by patients of group 1 and "modest" by those of group 2.
On day 20: in group 1 all the patients have stopped losing hair and report the presence of a substantial fuzz. In group 2 hair loss has stopped in 6 patients and fuzz, where present, is more modest (in terms of number/cm2) .
On day 45: in group 1, fuzz has grown markedly stronger and takes the colour and consistency of natural hair. In group 2, as expected, all the patients have stopped losing hair, but only some of them report a certain degree of regrowth, fuzz is very weak and not completely coloured yet.
On day 90: in group 1 all the patients report total disappearance of hair reduction areas that have been replaced by robust and shiny hair. In group 2 hair reduction is still visible, even if areas are all covered with thick fuzz.
On day 120: group 1 confirms results already seen at day 90. Group 2 continues improvement, even if in some patients of male gender the fuzz has not got the characteristics of strength and colour typical of hair yet.
During the whole phase of the study the patients' skin was regularly assayed by dermoscopy, highlighting an improvement of circulation. Additionally, treated skin did not display allergic or inflammatory reactions.
From the observations reported here, first of all, it can be inferred that the formulations object of the present invention are clinically efficient in:
· stopping hair loss; • promoting hair regrowth in areas with alopecia;
• strengthening and fortifying hair, bringing it back to its original state
both in male and female subjects with forms of hair reduction or actual alopecia due to different causes, and in menopausal women.
Formulations set up here additionally:
• do not contain potentially toxic substances or that may interfere with other active ingredients;
· are not irritating for the skin: even after long term application no evidence of irritation or inflammation was reported;
• are stable in time: analysis carried out on the content of the vials 30 days after preparation detects
· significant Ρζ values in terms of stability, particularly for formulations containing 2% or, better, 3% stearylamine
• an unchanged content of active substances enclosed in liposomes;
· can be stored at room temperature and in a ready-to- use form;
and, surprisingly
• act more quickly and more effectively: comparison tests clearly demonstrate that group 1 has a more rapid, more substantial improvement and, mainly, it involves all the patients as compared with group 2, treated with Lotion B.
Again, it should be recalled that Lotion B contains PGE1 and equol in 1:1 ratio, while Lotion A contains 30% less of active substance (DGLA) . This means that the findings of the present invention exert an unexpectedly superior effect than what known, at markedly lower concentrations of active substance."
https://patents.google.com/patent/EP3145490A1/en
"Clinical trials that were carried out further demonstrated a surprisingly higher efficacy of the products described herein in comparison with what is known, so as to make their use possible at concentrations markedly lower than those of already known products."
"
Lotions, eventually, can also be dispensed from "spray no-gas", then propellant free, bottles.
Additionally, it is possible to administer liposomes by oral route after having them properly delivered in capsules of gelatine or other substances suitable for the purpose and known to the expert in the field.
Regardless of the selected pharmaceutical form, it is clear that all excipients and all tactics known to the technical formulator in order to ensure stability, storability, absence of contamination, etc. of the preparations will be employed."
"The present invention relates to pharmaceutical compositions for the treatment of alopecia, baldness, hair loss, also in postmenopausal women, and in general to promote hair regrowth"
"Experimental study
Patients of female and male gender characterized by massive hair reduction due to various causes, and also a small number of patients of female gender of postmenopausal age, reporting hair thinning, hair reduction and loss of hair strength were selected."
"Results
On day 7 : both group 1 and group 2 experience a reduction of hair loss, defined "substantial" by patients of group 1 and "modest" by those of group 2.
On day 20: in group 1 all the patients have stopped losing hair and report the presence of a substantial fuzz. In group 2 hair loss has stopped in 6 patients and fuzz, where present, is more modest (in terms of number/cm2) .
On day 45: in group 1, fuzz has grown markedly stronger and takes the colour and consistency of natural hair. In group 2, as expected, all the patients have stopped losing hair, but only some of them report a certain degree of regrowth, fuzz is very weak and not completely coloured yet.
On day 90: in group 1 all the patients report total disappearance of hair reduction areas that have been replaced by robust and shiny hair. In group 2 hair reduction is still visible, even if areas are all covered with thick fuzz.
On day 120: group 1 confirms results already seen at day 90. Group 2 continues improvement, even if in some patients of male gender the fuzz has not got the characteristics of strength and colour typical of hair yet.
During the whole phase of the study the patients' skin was regularly assayed by dermoscopy, highlighting an improvement of circulation. Additionally, treated skin did not display allergic or inflammatory reactions.
From the observations reported here, first of all, it can be inferred that the formulations object of the present invention are clinically efficient in:
· stopping hair loss; • promoting hair regrowth in areas with alopecia;
• strengthening and fortifying hair, bringing it back to its original state
both in male and female subjects with forms of hair reduction or actual alopecia due to different causes, and in menopausal women.
Formulations set up here additionally:
• do not contain potentially toxic substances or that may interfere with other active ingredients;
· are not irritating for the skin: even after long term application no evidence of irritation or inflammation was reported;
• are stable in time: analysis carried out on the content of the vials 30 days after preparation detects
· significant Ρζ values in terms of stability, particularly for formulations containing 2% or, better, 3% stearylamine
• an unchanged content of active substances enclosed in liposomes;
· can be stored at room temperature and in a ready-to- use form;
and, surprisingly
• act more quickly and more effectively: comparison tests clearly demonstrate that group 1 has a more rapid, more substantial improvement and, mainly, it involves all the patients as compared with group 2, treated with Lotion B.
Again, it should be recalled that Lotion B contains PGE1 and equol in 1:1 ratio, while Lotion A contains 30% less of active substance (DGLA) . This means that the findings of the present invention exert an unexpectedly superior effect than what known, at markedly lower concentrations of active substance."